Paul A. Stewart,Eric A. Welsh,Robbert J. C. Slebos,Bin Fang,Victoria Izumi,Matthew Chambers,Guolin Zhang,Ling Cen,Fredrik Pettersson,Yonghong Zhang,Zhihua Chen,Chia-Ho Cheng,Ram Thapa,Zachary Thompson,Katherine M. Fellows,Jewel M. Francis,James J. Saller,Tania Mesa,Chaomei Zhang,Sean Yoder,Gina M. DeNicola,Amer A. Beg,Theresa A. Boyle,Jamie K. Teer,Yian Ann Chen,John M. Koomen,Steven A. Eschrich,Eric B. Haura

Abstract:How genomic and transcriptomic alterations affect the functional proteome in lung cancer is not fully understood. Here, we integrate DNA copy number, somatic mutations, RNA-sequencing, and expression proteomics in a cohort of 108 squamous cell lung cancer (SCC) patients. We identify three proteomic subtypes, two of which (Inflamed, Redox) comprise 87% of tumors. The Inflamed subtype is enriched with neutrophils, B-cells, and monocytes and expresses more PD-1 . Redox tumours are enriched for oxidation-reduction and glutathione pathways and harbor more NFE2L2/KEAP1 alterations and copy gain in the 3q2 locus. Proteomic subtypes are not associated with patient survival. However, B-cell-rich tertiary lymph node structures, more common in Inflamed, are associated with better survival. We identify metabolic vulnerabilities ( TP63 , PSAT1 , and TFRC ) in Redox. Our work provides a powerful resource for lung SCC biology and suggests therapeutic opportunities based on redox metabolism and immune cell infiltrates.

Proteogenomic landscape of squamous cell lung cancer